Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpointsEnrolled first patient in the U.S. COVID-19 study using the LungFit™ systemAnnounced positive pre-clinical data validating high concentration nitric oxide as a potential treatment for ablating solid tumors and inducing an anti-tumor immune responsePMA for the LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitted to the FDA in the second half of 2020LungFit™
Bay Street News